The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia
Open accessAbstract
Hyper-inflammatory responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are a major cause of disease severity and death. Predictive prognosis biomarkers to guide therapeutics are critically lacking. Several studies have indicated a “cytokine storm” with the release of interleukin-1 (IL-1), IL-6, and IL-8, along with tumor necrosis factor alpha (TNFα) and other inflammatory mediators. Here, we proposed to assess the relationship between IL-6 and outcomes of patients with coronavirus disease 2019 (COVID-19). Our cohort consisted of 46 adult patients with PCR-proven SARS-CoV-2 infection admitted in a COVID-19 ward of the Hospital de Braga (HB) from April 7 to May 7, 2020, whose IL-6 levels were followed over time. We found that IL-6 levels were significantly different between the disease stages. Also, we found a significant negative correlation between IL-6 levels during stages IIb and III, peripheral oxygen saturation (SpO 2), and partial pressure of oxygen in arterial blood (PaO 2), showing that IL-6 correlates with respiratory failure. Compared to the inflammatory markers available in the clinic routine, we found a positive correlation between IL-6 and C-reactive protein (CRP). However, when we assessed the predictive value of these two markers, IL-6 behaves as a better predictor of disease progression. In a binary logistic regression, IL-6 level was the most significant predictor of the non-survivors group, when compared to age and CRP. Herein, we present IL-6 as a relevant tool for prognostic evaluation, mainly as a predictor of outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
(2014) · Climate Change 2013 – The Physical Science Basis · doi:10.1017/cbo9781107415324.004 · Cited by 23,880
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475 · cited 7×
“Active Neoplasia 1 (20) 3 (20) 1 (9) 0.”
BackgroundResultInfluentialRemdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661 · cited 2×
“Hydroxychloroquine + azithromycin 19 (41)”
BackgroundWiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
To, K. K.-W., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C.-Y., Cai, J.-P., Chan, J. M.-C., Chik, T. S.-H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,066
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
WHO Solidarity Trial Consortium (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023184 · Cited by 2,745
An inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, J. A. C., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., Angus, D. C., Annane, D., Azevedo, L. C. P., Berwanger, O., et al. (2020) · JAMA · doi:10.1001/jama.2020.17023 · Cited by 2,257
COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
Siddiqi, H. K., & Mehra, M. R. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.03.012 · Cited by 1,701
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362
Spinner, C. D., Gottlieb, R. L., Criner, G. J., Arribas López, J. R., Cattelan, A. M., Soriano Viladomiu, A., Ogbuagu, O., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,211
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., Klein, M., & Weinberger, T. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.008 · Cited by 1,161
Han, H., Ma, Q., Li, C., Liu, R., Zhao, L., Wang, W., Zhang, P., Liu, X., Gao, G., Liu, F., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1770129 · Cited by 1,148
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30173-9 · Cited by 939
Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment
Soy, M., Keser, G., Atagündüz, P., Tabak, F., Atagündüz, I., & Kayhan, S. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05190-5 · Cited by 811
Hermine, O., Mariette, X., Tharaux, P.-L., Resche-Rigon, M., Porcher, R., Ravaud, P., CORIMUNO-19 Collaborative Group, Bureau, S., Dougados, M., Tibi, A., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6820 · Cited by 734
Immunotherapeutic Implications of Il-6 Blockade for Cytokine Storm
Tanaka, T., Narazaki, M., & Kishimoto, T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0020 · Cited by 708
Salvarani, C., Dolci, G., Massari, M., Merlo, D. F., Cavuto, S., Savoldi, L., Bruzzi, P., Boni, F., Braglia, L., Turrà, C., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6615 · Cited by 684
Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis
Aziz, M., Fatima, R., & Assaly, R. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25948 · Cited by 554
The Role of Interleukin 6 During Viral Infections
Velazquez-Salinas, L., Verdugo-Rodriguez, A., Rodriguez, L. L., & Borca, M. V. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01057 · Cited by 526
The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019
Liu, T., Zhang, J., Yang, Y., Ma, H., Li, Z., Zhang, J., Cheng, J., Zhang, X., Zhao, Y., Xia, Z., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012421 · Cited by 498
Sarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
Behrens, E. M., & Koretzky, G. A. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40071 · Cited by 304
A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe
Borobia, A., Carcas, A., Arnalich, F., Álvarez-Sala, R., Monserrat-Villatoro, J., Quintana, M., Figueira, J., Torres Santos-Olmo, R., García-Rodríguez, J., Martín-Vega, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061733 · Cited by 288
Dienz, O., Rud, J. G., Eaton, S. M., Lanthier, P. A., Burg, E., Drew, A., Bunn, J., Suratt, B. T., Haynes, L., & Rincon, M. (2012) · Mucosal Immunology · doi:10.1038/mi.2012.2 · Cited by 275
Tleyjeh, I. M., Kashour, Z., Damlaj, M., Riaz, M., Tlayjeh, H., Altannir, M., Altannir, Y., Al-Tannir, M., Tleyjeh, R., Hassett, L., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.10.036 · Cited by 205
IL-6–based mortality risk model for hospitalized patients with COVID-19
Laguna-Goya, R., Utrero-Rico, A., Talayero, P., Lasa-Lazaro, M., Ramirez-Fernandez, A., Naranjo, L., Segura-Tudela, A., Cabrera-Marante, O., Rodriguez de Frias, E., Garcia-Garcia, R., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.009 · Cited by 204
Interleukin-6 as prognosticator in patients with COVID-19
Grifoni, E., Valoriani, A., Cei, F., Lamanna, R., Gelli, A. M. G., Ciambotti, B., Vannucchi, V., Moroni, F., Pelagatti, L., Tarquini, R., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.06.008 · Cited by 190
COVID-19 as an Acute Inflammatory Disease
Manjili, R. H., Zarei, M., Habibi, M., & Manjili, M. H. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000413 · Cited by 176
IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?
Atal, S., & Fatima, Z. (2020) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00342-z · Cited by 166
SARS-CoV-2 and COVID-19: From the Bench to the Bedside
Romagnoli, S., Peris, A., Gaudio, A. R. D., & Geppetti, P. (2020) · Physiological Reviews · doi:10.1152/physrev.00020.2020 · Cited by 153
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications
Iannaccone, G., Scacciavillani, R., Buono, M. G. D., Camilli, M., Ronco, C., Lavie, C. J., Abbate, A., Crea, F., Massetti, M., & Aspromonte, N. (2020) · Cardiorenal Medicine · doi:10.1159/000509483 · Cited by 123
Review of trials currently testing treatment and prevention of COVID-19
Fragkou, P. C., Belhadi, D., Peiffer‐Smadja, N., Moschopoulos, C. D., Lescure, F.-X., Janocha, H., Karofylakis, E., Yazdanpanah, Y., Mentré, F., Skevaki, C. L., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.05.019 · Cited by 98
Niszczota, P., & Kaszás, D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239277 · Cited by 82
Vultaggio, A., Vivarelli, E., Virgili, G., Lucenteforte, E., Bartoloni, A., Nozzoli, C., Morettini, A., Berni, A., Malandrino, D., Rossi, O., et al. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.06.013 · Cited by 74
Dynamic Interleukin-6 Level Changes as a Prognostic Indicator in Patients With COVID-19
Liu, Z., Li, J., Chen, D., Gao, R., Zeng, W., Chen, S., Huang, Y., Huang, J., Long, W., Li, M., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01093 · Cited by 73
Fungal Biodiversity of the Most Common Types of Polish Soil in a Long-Term Microplot Experiment
Grządziel, J., & Gałązka, A. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00006 · Cited by 72
COVID‐19 and the Canadian cattle/beef sector: Some preliminary analysis
Rude, J. I. (2020) · Canadian Journal of Agricultural Economics/Revue canadienne d agroeconomie · doi:10.1111/cjag.12228 · Cited by 71
Syed, F., & Yu, Q. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25577 · Cited by 53
Focus shifts to antibody cocktails for COVID-19 cytokine storm
Harrison, C. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0634-9 · Cited by 48
Obstructive Sleep Apnea as a Predictor of Abnormal Heart Rate Turbulence
Urbanik, D., Gać, P., Martynowicz, H., Poręba, M., Podgórski, M., Negrusz‐Kawecka, M., Mazur, G. J., Sobieszczańska, M. I., & Poręba, R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010001 · Cited by 39
Chronic treatment with hydroxychloroquine and SARS‐CoV‐2 infection
Ferreira, A., Oliveira‐e‐Silva, A., & Bettencourt, P. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26286 · Cited by 36
Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab
Salvati, L., Occhipinti, M., Gori, L., Ciani, L., Mazzoni, A., Maggi, L., Capone, M., Parronchi, P., Liotta, F., Miele, V., et al. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.10.009 · Cited by 18
Cited by
Savin, I. A., Zenkova, M. A., & Sen’kova, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314959 · Cited by 279
Emerging insights in senescence: pathways from preclinical models to therapeutic innovations
Mansfield, L., Ramponi, V., Gupta, K., Stevenson, T., Mathew, A. B., Barinda, A. J., Herbstein, F., & Morsli, S. (2024) · npj Aging · doi:10.1038/s41514-024-00181-1 · Cited by 88
COVID-19 as a Risk Factor for Alzheimer’s Disease
Golzari-Sorkheh, M., Weaver, D. F., & Reed, M. A. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-220800 · Cited by 39
Lionte, C., Sorodoc, V., Haliga, R. E., Bologa, C., Ceasovschih, A., Petris, O. R., Coman, A. E., Stoica, A., Sirbu, O., Puha, G., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12061373 · Cited by 36
Post-COVID-19 Parkinsonism and Parkinson’s Disease Pathogenesis: The Exosomal Cargo Hypothesis
Mysiris, D. S., Vavougios, G. D., Karamichali, E., Papoutsopoulou, S., Stavrou, V. T., Papayianni, E., Boutlas, S., Mavridis, T., Foka, P., Zarogiannis, S. G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179739 · Cited by 25
Metadata
- Authors
- Santa Cruz, A., Mendes-Frias, A., Oliveira, A. I., Dias, L., Matos, A. R., Carvalho, A., Capela, C., Pedrosa, J., Castro, A. G., & Silvestre, R.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-02-18
- Volume
- 12
- Pages
- 613422-613422
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3129397954
- Cited by
- 355
- References
- 51
- FWCI
- 22.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.